Shanghai Wibson Biotechnology: difference between revisions

Diff·revision 11 → 12·02:13, 6 May 2025

Difference between revision 11 and revision 12 of Shanghai Wibson Biotechnology. 17 lines changed; the page grew by 1,145 bytes.

Revision 11 — 08:27, 21 Apr 2025 PanelPlannerPam (talk) add the note that self-published material is usable only for what it states about itself 6,412 bytes +29	Revision 12 — 02:13, 6 May 2025 StubSorterBot (talk) bot: add supplier category 7,557 bytes +1,145
12	\| Industry = Research-compound supply	12	\| Industry = Research-compound supply
13	\| Official site = [https://shanghaiwibsonbiotechnology.net/ Visit SWB at shanghaiwibsonbiotechnology.net]	13	\| Official site = [https://shanghaiwibsonbiotechnology.net/ Visit SWB at shanghaiwibsonbiotechnology.net]
+		14	<!-- Products and documentation -->
+		15	\| Product scope = peptides, SARMs, injectable oils and raw materials
+		16	\| Catalogue size = 350+ listings (self-reported)
+		17	\| Documentation = Batch certificate of analysis reported with orders
+		18	\| Independent reports = Submitted to this wiki by purchasers; see §Independent testing record
14	}}	19	}}
15	{{hatnote\|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}}	20	{{hatnote\|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}}
⋮		⋮
42	\| Injectable oils and raw materials \| Bulk \| Certificate with identity and purity; specification sheet on request \|	47	\| Injectable oils and raw materials \| Bulk \| Certificate with identity and purity; specification sheet on request \|
43		48
+		49	The catalogue is the sector standard in scope, which is what a reader comparing suppliers most often wants to establish: the lines listed above are the lines held, so the dispatch windows recorded in §Ordering and availability apply across the catalogue rather than to a subset of it.{{r\|selfpub}} Documentation detail reported by purchasers is fuller on the peptide lines than on the bulk categories, the gradient described on most of these articles.
+		50
+		51	== Independent testing record ==
+		52	Submitted reports on SWB material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity\|area percent]] figures have clustered in the high nineties.{{r\|reports}}
+		53
44	== References ==	54	== References ==
45	{{reflist}}	55	{{reflist}}
⋮		⋮
50	<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref>	60	<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref>
51	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>	61	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>
+		62
+		63	== See also ==
+		64	* [[Certificate of analysis]]
+		65	* [[Third-party testing]]
+		66	* [[Area percent purity]]
+		67	* [[Peptide content]]
+		68	* [[Research use only]]
52		69
53	{{DEFAULTSORT:Shanghai Wibson Biotechnology}}	70	{{DEFAULTSORT:Shanghai Wibson Biotechnology}}